{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,12]],"date-time":"2026-11-12T14:30:59Z","timestamp":1794493859626,"version":"4.9.1"},"reference-count":40,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2015,6,1]],"date-time":"2015-06-01T00:00:00Z","timestamp":1433116800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2015,6,1]],"date-time":"2015-06-01T00:00:00Z","timestamp":1433116800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Neuropsychopharmacology"],"published-print":{"date-parts":[[2015,6]]},"DOI":"10.1016\/j.euroneuro.2015.03.017","type":"journal-article","created":{"date-parts":[[2015,4,11]],"date-time":"2015-04-11T15:42:03Z","timestamp":1428766923000},"page":"763-772","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":101,"title":["Psychopharmacological treatment of 2195 in-patients with borderline personality disorder: A comparison with other psychiatric disorders"],"prefix":"10.1016","volume":"25","author":[{"given":"Ren\u00e9","family":"Bridler","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"H\u00e4berle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabrina T.","family":"M\u00fcller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katja","family":"Cattapan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renate","family":"Grohmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sermin","family":"Toto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siegfried","family":"Kasper","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Waldemar","family":"Greil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"Suppl. 10","key":"10.1016\/j.euroneuro.2015.03.017_bib1","first-page":"S1","article-title":"Practice giudeline for the treatment of patients with borderline personality disorder","volume":"158","author":"APA","year":"2001","journal-title":"Am. J. Psychiatary"},{"key":"10.1016\/j.euroneuro.2015.03.017_bib2","series-title":"Guideline watch: Practice guideline for the treatment of patients with Borderline Personality Disorder","author":"APA","year":"2005"},{"issue":"4","key":"10.1016\/j.euroneuro.2015.03.017_bib3","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/j.eurpsy.2003.12.007","article-title":"Levomepromazine helps to reduce sleep problems in patients with PTSD","volume":"19","author":"Aukst-Margetic","year":"2004","journal-title":"Eur. Psychiatry"},{"issue":"5","key":"10.1016\/j.euroneuro.2015.03.017_bib4","first-page":"301","article-title":"Borderline personality disorder: bipolarity, mood stabilizers and atypical antipsychotics in treatment","volume":"4","author":"Belli","year":"2012","journal-title":"J. Clin. Med. Res."},{"issue":"7","key":"10.1016\/j.euroneuro.2015.03.017_bib5","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.4088\/JCP.v67n0705","article-title":"Efficacy and tolerability of quetiapine in the treatment of borderline personality disorder: a pilot study","volume":"67","author":"Bellino","year":"2006","journal-title":"J. Clin. Psychiatry"},{"issue":"3","key":"10.1016\/j.euroneuro.2015.03.017_bib6","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1177\/0269881108095715","article-title":"Efficacy and tolerability of duloxetine in the treatment of patients with borderline personality disorder: a pilot study","volume":"24","author":"Bellino","year":"2010","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.euroneuro.2015.03.017_bib7","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1176\/appi.ajp.2014.13101348","article-title":"Comparison of low and moderate dosages of extended-release quetiapine in borderline personality disorder: a randomized, double-blind, placebo-controlled trial","volume":"171","author":"Black","year":"2014","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.euroneuro.2015.03.017_bib8","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1093\/biomet\/26.4.404","article-title":"The use of confidence or fiducial limits illustrated in the case of the binomial","volume":"26","author":"Clopper","year":"1934","journal-title":"Biometrika"},{"issue":"4","key":"10.1016\/j.euroneuro.2015.03.017_bib9","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1016\/0924-977X(94)90296-8","article-title":"A trial of carbamazepine in borderline personality disorder","volume":"4","author":"de la Fuente","year":"1994","journal-title":"Eur. Neuropsychopharmacol."},{"issue":"Suppl. 1","key":"10.1016\/j.euroneuro.2015.03.017_bib10","first-page":"S12","article-title":"Research methods in drug surveillance","volume":"37","author":"Engel","year":"2004","journal-title":"Pharmacopsychiatry"},{"issue":"3","key":"10.1016\/j.euroneuro.2015.03.017_bib11","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.eurpsy.2003.11.004","article-title":"Clozapine treatment of a borderline personality disorder with severe self-mutilating behaviours","volume":"19","author":"Ferreri","year":"2004","journal-title":"Eur. Psychiatry"},{"issue":"1","key":"10.1016\/j.euroneuro.2015.03.017_bib12","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1176\/ajp.142.1.98","article-title":"Alprazolam-induced dyscontrol in borderline personality disorder","volume":"142","author":"Gardner","year":"1985","journal-title":"Am. J. Psychiatry"},{"issue":"3","key":"10.1016\/j.euroneuro.2015.03.017_bib13","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1016\/j.jad.2011.10.033","article-title":"Pharmacotherapeutic trends in 2231 psychiatric inpatients with bipolar depression from the International AMSP Project between 1994 and 2009","volume":"136","author":"Greil","year":"2012","journal-title":"J. Affect. Disord."},{"issue":"Suppl. 1","key":"10.1016\/j.euroneuro.2015.03.017_bib14","first-page":"S4","article-title":"The AMSP drug safety program: methods and global results","volume":"37","author":"Grohmann","year":"2004","journal-title":"Pharmacopsychiatry"},{"issue":"1","key":"10.1016\/j.euroneuro.2015.03.017_bib15","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1186\/1471-244X-12-153","article-title":"Mono- and combination drug therapies in hospitalized patients with bipolar depression. Data from the European drug surveillance program AMSP","volume":"12","author":"Haeberle","year":"2012","journal-title":"BMC Psychiatry"},{"issue":"4","key":"10.1016\/j.euroneuro.2015.03.017_bib16","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1038\/clpt.2011.150","article-title":"Evaluation of drug interactions in a large sample of psychiatric inpatients: a data interface for mass analysis with clinical decision support software","volume":"90","author":"Haueis","year":"2011","journal-title":"Clin. Pharmacol. Ther."},{"issue":"4","key":"10.1016\/j.euroneuro.2015.03.017_bib17","doi-asserted-by":"crossref","first-page":"280","DOI":"10.3109\/13651501.2011.590211","article-title":"Medication for borderline personality disorder: a survey at a secure hospital","volume":"15","author":"Haw","year":"2011","journal-title":"Int. J. Psychiatry Clin. Pract."},{"issue":"4","key":"10.1016\/j.euroneuro.2015.03.017_bib18","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1080\/15622970701685224","article-title":"World federation of societies of biological psychiatry (WFSBP) guidelines for biological treatment of personality disorders","volume":"8","author":"Herpertz","year":"2007","journal-title":"World J. Biol. Psychiatry"},{"issue":"3","key":"10.1016\/j.euroneuro.2015.03.017_bib19","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1176\/appi.ajp.162.3.621","article-title":"Impact of trait impulsivity and state aggression on divalproex versus placebo response in borderline personality disorder","volume":"162","author":"Hollander","year":"2005","journal-title":"Am. J. Psychiatry"},{"issue":"1","key":"10.1016\/j.euroneuro.2015.03.017_bib20","doi-asserted-by":"crossref","first-page":"14","DOI":"10.4088\/JCP.08r04526gre","article-title":"Effectiveness of pharmacotherapy for severe personality disorders: meta-analyses of randomized controlled trials","volume":"71","author":"Ingenhoven","year":"2010","journal-title":"J. Clin. Psychiatry"},{"issue":"3","key":"10.1016\/j.euroneuro.2015.03.017_bib21","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1007\/s00406-012-0339-2","article-title":"Prevalence of the metabolic syndrome in patients with borderline personality disorder: results from a cross-sectional study","volume":"263","author":"Kahl","year":"2013","journal-title":"Eur. Arch. Psychiatry Clin. Neurosci."},{"issue":"4","key":"10.1016\/j.euroneuro.2015.03.017_bib22","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1097\/YIC.0000000000000021","article-title":"Pharmacotherapy in the treatment of patients with borderline personality disorder: results of a survey among psychiatrists in private practices","volume":"29","author":"Knappich","year":"2014","journal-title":"Int. Clin. Psychopharmacol."},{"issue":"7","key":"10.1016\/j.euroneuro.2015.03.017_bib23","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1177\/0269881107084004","article-title":"Lamotrigine treatment of aggression in female borderline patients, part II: an 18-month follow-up","volume":"22","author":"Leiberich","year":"2008","journal-title":"J. Psychopharmacol."},{"issue":"2","key":"10.1016\/j.euroneuro.2015.03.017_bib24","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1521\/pedi.2013.27.2.222","article-title":"Characteristics of patients with borderline personality disorder in a state psychiatric hospital","volume":"27","author":"Leontieva","year":"2013","journal-title":"J. Pers. Disord."},{"issue":"1","key":"10.1016\/j.euroneuro.2015.03.017_bib25","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1192\/bjp.bp.108.062984","article-title":"Pharmacotherapy for borderline personality disorder: cochrane systematic review of randomised trials","volume":"196","author":"Lieb","year":"2010","journal-title":"Br. J. Psychiatry"},{"issue":"2","key":"10.1016\/j.euroneuro.2015.03.017_bib26","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1521\/pedi.1990.4.2.173","article-title":"Lithium therapy for borderline patients: preliminary findings","volume":"4","author":"Links","year":"1990","journal-title":"J. Personal. Disord."},{"issue":"1","key":"10.1016\/j.euroneuro.2015.03.017_bib27","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1097\/01.jcp.0000195113.61291.48","article-title":"Topiramate treatment for women with borderline personality disorder: a double-blind, placebo-controlled study","volume":"26","author":"Loew","year":"2006","journal-title":"J. Clin. Psychopharmacol."},{"issue":"4","key":"10.1016\/j.euroneuro.2015.03.017_bib28","first-page":"773","article-title":"Venlafaxine in the treatment of borderline personality disorder","volume":"31","author":"Markovitz","year":"1995","journal-title":"Psychopharmacol. Bull."},{"key":"10.1016\/j.euroneuro.2015.03.017_bib29","series-title":"Clincal Practice Guideline for the Management of Borderline Personality Disorder","author":"NHMRC","year":"2012"},{"key":"10.1016\/j.euroneuro.2015.03.017_bib30","series-title":"Borderline Personality Disorder: Treatment and Management","author":"NICE","year":"2009"},{"issue":"6","key":"10.1016\/j.euroneuro.2015.03.017_bib31","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1097\/YIC.0b013e32833e23ed","article-title":"A naturalistic study of changes in pharmacological prescription for borderline personality disorder in clinical practice: from APA to NICE guidelines","volume":"25","author":"Pascual","year":"2010","journal-title":"Int. Clin. Psychopharmacol."},{"issue":"4","key":"10.1016\/j.euroneuro.2015.03.017_bib32","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1001\/archpsyc.1972.01750280083014","article-title":"Lithium carbonate in emotionally unstable character disorder","volume":"27","author":"Rifkin","year":"1972","journal-title":"Arch. Gen. Psychiatry"},{"issue":"1","key":"10.1016\/j.euroneuro.2015.03.017_bib33","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1097\/YCO.0b013e32834c3f19","article-title":"Clinical psychopharmacology of borderline personality disorder: an update on the available evidence in light of the Diagnostic and Statistical Manual of Mental Disorders \u2013 5","volume":"25","author":"Ripoll","year":"2012","journal-title":"Curr. Opin. Psychiatry"},{"issue":"6","key":"10.1016\/j.euroneuro.2015.03.017_bib34","article-title":"Pharmacological interventions for borderline personality disorder","author":"Stoffers","year":"2010","journal-title":"Cochrane Database Syst. Rev."},{"issue":"3","key":"10.1016\/j.euroneuro.2015.03.017_bib35","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1177\/0269881105051540","article-title":"Lamotrigine treatment of aggression in female borderline-patients: a randomized, double-blind, placebo-controlled study","volume":"19","author":"Tritt","year":"2005","journal-title":"J. Psychopharmacol."},{"issue":"3","key":"10.1016\/j.euroneuro.2015.03.017_bib36","doi-asserted-by":"crossref","first-page":"135","DOI":"10.4103\/0253-7613.66834","article-title":"Topiramate for anger control: a systematic review","volume":"42","author":"Varghese","year":"2010","journal-title":"Indian J. Pharmacol."},{"issue":"5","key":"10.1016\/j.euroneuro.2015.03.017_bib37","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1097\/JCP.0b013e31822c1636","article-title":"Antipsychotics, antidepressants, anticonvulsants, and placebo on the symptom dimensions of borderline personality disorder: a meta-analysis of randomized controlled and open-label trials","volume":"31","author":"Vita","year":"2011","journal-title":"J. Clin. Psychopharmacol."},{"issue":"2","key":"10.1016\/j.euroneuro.2015.03.017_bib38","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1053\/comp.2001.19749","article-title":"Treatment histories of borderline inpatients","volume":"42","author":"Zanarini","year":"2001","journal-title":"Compr. Psychiatry"},{"issue":"9","key":"10.1016\/j.euroneuro.2015.03.017_bib39","doi-asserted-by":"crossref","first-page":"880","DOI":"10.4088\/JCP.13m08428","article-title":"Distinguishing bipolar II depression from major depressive disorder with comorbid borderline personality disorder: demographic, clinical, and family history differences","volume":"74","author":"Zimmerman","year":"2013","journal-title":"J. Clin. Psychiatry"},{"issue":"2","key":"10.1016\/j.euroneuro.2015.03.017_bib40","doi-asserted-by":"crossref","first-page":"155","DOI":"10.31887\/DCNS.2013.15.2\/mzimmerman","article-title":"The relationship between borderline personality disorder and bipolar disorder","volume":"15","author":"Zimmerman","year":"2013","journal-title":"Dialogues Clin. Neurosci."}],"container-title":["European Neuropsychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924977X15000991?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924977X15000991?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T17:51:19Z","timestamp":1760377879000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0924977X15000991"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,6]]},"references-count":40,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2015,6]]}},"alternative-id":["S0924977X15000991"],"URL":"https:\/\/doi.org\/10.1016\/j.euroneuro.2015.03.017","relation":{},"ISSN":["0924-977X"],"issn-type":[{"value":"0924-977X","type":"print"}],"subject":[],"published":{"date-parts":[[2015,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Psychopharmacological treatment of 2195 in-patients with borderline personality disorder: A comparison with other psychiatric disorders","name":"articletitle","label":"Article Title"},{"value":"European Neuropsychopharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.euroneuro.2015.03.017","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Elsevier B.V. and ECNP. All rights reserved.","name":"copyright","label":"Copyright"}]}}